A prospective, randomized, probe trial to evaluate whether, at comparable blood pressure control, combined therapy with the ACEI (angiotensin converting enzyme inhibitors) benazepril and the ARB (angiotensin II receptor blockers) valsartan, reduces the incidence of microalbuminuria more effectively than BEN (benazepril) or VAL (valsartan) alone in hypertensive patients with type 2 diabetes and high-normal albuminuria
Latest Information Update: 11 Nov 2021
At a glance
- Drugs Benazepril (Primary) ; Valsartan (Primary)
- Indications Diabetic nephropathies; Hypertension; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms VARIETY
- 24 May 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 16 Aug 2007 New trial record.